Abstract library

923 results for "metastatic gastric carcinoids".
#2711 Gastric Neuroendocrine Neoplasms: Clinical Management and Outcomes in a Cohort of 54 Patients
Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10-20% can be type 3 or type 4 Gastric NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Alexandra Victor
Authors: Victor A, Ramage J, Cope J, Maclean R, ...
#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Filomena Bottiglieri
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids
Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Patricia Borges de Souza
#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Housestaff Mary Wong
Authors: Wong M, Huynh C, Kim S, Dhall D, ...
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#295 Unusual Behavior of Gastric Carcinoid Type 1
Introduction: Gastric carcinoids (GC) are rare tumors of the stomach. GC type 1 are associated with chronic atrophic gastritis (CAG) and are the most benign type, having low metastatic potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Matilde P Spampatti
#802 Metastatic Type 1 Gastric Carcinoid - A Real Threat or Just a Myth?
Introduction: Metastatic GCA1 are extremely rare and there is no data about their natural history, treatment and prognosis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: ...none of the below
Presenting Author: Dr. Simona Glasberg